Abstract: Along the entire lifetime, Notch is actively involved in dynamic changes in the cellular architecture and function of the nervous system. It controls neurogene sis, the growth of axons and dendrites, synaptic plastic ity, and ultimately neuronal death. The specific roles of Notch in adult brain plasticity and neurological disorders have begun to be unraveled in recent years, and pieces of experimental evidence suggest that Notch is operative in diverse brain pathologies including tumorigenesis, stroke, and neurological disorders such as Alzheimer's disease, Down syndrome, and multiple sclerosis. In this review, we will cover the recent findings of Notch signaling and neural dysfunction in adult human brain and discuss its relevance in the pathogenesis of diseases of the central nervous system.
Introduction
Along the entire lifetime, Notch is actively involved in dynamic changes in the cellular architecture and function of the nervous system. Most of Notch target genes encode transcription regulators, many of which are critical in central nervous system (CNS) development. However, cell fate determination or other events influenced by Notch signaling can also result in the absence of transcriptional activation. In the CNS, Notch protein and ligands are not only present in the embryonic stages but also continuously in the adult nervous system. Recent studies have led to the recognition of the role of the Notch pathway in learning and memory, as well as latelife neurodegeneration. Notch controls neurogenesis, the growth of axons and dendrites, synaptic plasticity, and ultimately neuronal death. In the following, we review the cellular processes in the patho logic adult brain in which Notch signaling is involved and its impact on brain functionality.
Notch signal transduction
Notch signaling is unidirectional, with a 'signalsending cell' that presents the Notch ligand to the 'signalreceiving cell', which expresses the Notch receptor. Notch recep tors are singlepass transmembrane proteins with differ ent domains that maintain the receptor as inactive in the absence of ligands (1, 2) . These receptors are covered with a variety of glycans, and it is now clear that glycans modu late Notch signaling; however, it is not clearly known how this occurs (3) . The Notch pathway in adult brain com prises multiple subtypes of ligands and receptors with differential expression patterns, which are summarized in Table 1 . Mechanistically, Notch ligands are presented on the cell membrane and are subsequently endocytosed. These ligands can be 'activated' by an asyetunknown mechanism and represented to the membrane. Notch receptors are synthesized as a single peptide and then cleaved in the Golgi compartment to form a heterodimer that is presented on the cell membrane. Once on the mem brane, the ligand can bind Notch. It was proposed that the Notch heterodimer is pulled apart through the force of endocytosis in the signalsending cell, and then, the Notch extracellular domain (NECD) is endocytosed. The Notch domain that remains on the signalreceiving cell is sequentially cleaved by αsecretase, via A disintegrin and metalloproteinase (ADAM) 10 (4) and by the γsecretase complex to release the Notch intracellular domain (NICD). Through a convergence of genetic, pharmacologi cal, protein, and cell biology studies, it is now clear that γsecretase is a multisubunit aspartyl protease that cleaves more than 70 type 1 transmembrane proteins within their transmembrane domains. Presenilin 1 and Presenilin 2 (PS1 and PS2) form the catalytic core of γsecretase and three accessory proteins, anterior pharynxdefective 1 (APH1), nicastrin (Nct), and presenilin enhancer protein 2 (PEN2), are required to complete the γsecretase complex (5). The precise location of the γsecretase cleavage is controversial, with some data indicating the endosome as the major site although there is some evidence sug gesting that cleavage can also take place at the plasma membrane, leading to different NICD molecules. Nuclear responses due to Notch activation are tightly regulated by various posttranslational modifications that affect NICD trafficking, halflife, and transcriptional activity, thereby contributing to signaling diversity (6) . Over the past decades, important progress has been made in decipher ing Notch signal transduction and identifying processes that are influenced by Notch (1) . The emerging picture posits that in the 'canonical' signaling pathway (Figure 1 ), most Notchdependent physiological and pathological processes rely on the ability of nuclear NICD to convert the Co-A HDACs Figure 1 Canonical Notch signal transduction.The Notch receptor in the 'signal-receiving cell' is activated by binding to canonical ligands (DSL/DOS) presented by a 'signal-sending cell'. Endocytosis and membrane trafficking regulate ligand and receptor availability at the cell surface. Ligand endocytosis is also thought to generate sufficient force to promote a conformational change that exposes Notch to cleavage by ADAM metalloproteases. Juxtamembrane cleavage generates the membrane-anchored Notch extracellular truncation (NEXT) fragment, which is a substrate for the γ-secretase complex. γ-Secretase complex cleaves the Notch transmembrane domain to release NICD and Nβ peptides. In the absence of NICD, the DNA-binding protein CSL associates with ubiquitous corepressor (Co-R) proteins and histone deacetylases (HDACs) to repress transcription of target genes. When NICD enters the nucleus, its binding to CSL may trigger an allosteric change that facilitates displacement of transcriptional repressors. Mastermind (MAM) then recognizes the NICD/CSL interface, and this tri-protein complex recruits coactivators (Co-A) to activate transcription.
DNAbinding protein CSL from a transcriptional repres sor into an activator. This regulation involves the forma tion of a stable ternary complex composed of CSL, NICD, and mastermindlike family of coactivators (MAML) (7, 8) . Deciphering how this complex orchestrates transcrip tional activation and how diversity in the transcriptional program is established depending on the cellular context is a major challenge in the field. The most studied Notch targets are the hairy and enhancer of splitrelated genes, which are members of the bHLH family of transcriptional repressors (9) . However, many additional genes have been recently identified as Notch targets (10) . In addition, NICD can also signal in the absence of transcriptional activa tion presumably through proteinprotein interactions, a pathway collectively known as 'noncanonical' signaling (11) . Noncanonical Notch signaling can be either ligand dependent or independent. The betterdescribed function of the latter is the antagonism of Wnt/βcatenin pathway, an evolutionary conserved mechanism that defines the main body axis of vertebrates (12) (13) (14) (15) (16) . Wnt signaling is activated by the binding of Wnt protein (the ligand) to a frizzled family receptor, which passes the biologi cal signal to the protein dishevelled inside the cell. The three bestcharacterized Wnt signaling pathways are the canonical, the noncanonical planar cell polarity, and the noncanonical Wnt/calcium, respectively. The differ ence among them is that the canonical pathway involves the protein βcatenin. Stabilized βcatenin can enter the nucleus and activate several genes that induce dorsal cell characteristics (13) . The link between Notch and βcatenin was confirmed in Drosophila and Xenopus (17) (18) (19) sug gesting that Notch antagonizes Wnt signaling by promot ing βcatenin degradation. Notch/βcatenin interaction is important in the development to control the size and anteriorposterior pattern of the brain (20) supporting the noncanonical function of Notch as a downregulator of constitutive Wnt activity (17, 19) . Regarding noncanonical ligand dependent Notch signaling, it was demonstrated that its major impact is on axon patterning through NICD interaction with the AbI cytoplasmic pathway (21) (22) (23) (24) . Molecularly, NICD binds to and suppresses the effects of two cofactors of Abl tyrosine kinase (23, 25, 26) controlling the actin structure and dynamics in the growth cone (22) .
Notch activation and neurogenesis in adult brain
Notch pathway components are expressed in the neuro genic 'niches', specialized cellular microenvironments that modulate stem cell properties, including cell number, selfrenewal, and fate decisions. In the adult brain, 'niches' that maintain a source of neural stem cells (NSCs) are the subventricular zone (SVZ) of the lateral ventricle and the dentate gyrus (DG) of the hippocampus. Persis tence of neurogenesis in adulthood was identified more than a decade ago (32) and refers to the process by which new neurons are produced from NSCs in the adult brain.
Physiologically, in the neurogenic 'niche', NSCs produce transient intermediate precursors (IP), which generate neuroblasts that exit the cell cycle and differentiate into neurons. The precise dynamics of neuron production from the NSCs remains controversial. Notch signaling is a key mediator of NSCs maintenance, suppressing the expres sion of proneural genes including Ascl1 and supporting the progenitor cell survival. The opposing states of qui escence vs. proliferation are controlled by Notch levels and seem to be celldependent: low levels of Notch lead to proliferation of NSCs and high levels, growth arrest (34). However, it was reported that neural progenitors are less responsive to Notch and more sensitive to environmental factors for the regulation of proliferation (27) . If levels of Notch signaling remain low and growth factors are with drawn, cells exit the cycle and differentiate into neurons. It was recently demonstrated that after the initiation of neu rogenesis, cells remain at the immature neuron stage for weeks or months, allowing them to adapt to physiological or pathophysiological stimuli that may affect their matu ration and differentiation (28) . It has become increasingly evident that NSC selfrenewal and differen tiation in the SVZ and hippocampus are regulated by factors secreted by nonneuronal cell types, including microglia (35), endothelial cells (36, 37) or astrocytes (38) (39) (40) (41) and that differences in the microenvironment and signaling path ways govern the two adult neurogenic niches (42) (43) (44) . A schematic representation of NICD role in NSC renewal, cell cycle progression, and cell fate decision is depicted in Figure 2 . In addition to neurogenic niches, Notch is also expressed throughout the adult brain, pointing at addi tional functions beyond its role in stem cell maintenance and differentiation. It was demonstrated that activation of the mammalian Notch pathway occurs reiteratively in migratory and postmitotic neurons, supporting that Notch acts as a master regulator of plasticity and neuronal migration.
Notch activation and neural dysfunction
The importance of Notch signaling for normal human adult brain function is demonstrated by its implica tions in neurological diseases as diverse as the Alagille syndrome, a developmental disorder associated with mental retardation (29) , cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencepha lopathy (CADASIL) (30) , and certain types of schizophre nia (31) . All of them show functional mutations in key components of the Notch pathway. Late onset CADASIL and the Alagille syndrome are associated with mutations in, respectively, Notch3 and JaggeD1 genes, while a Notch4 polymorphism is strongly associated with sus ceptibility to schizophrenia. In addition, gene expression and immunohistochemical studies show that Notch is overexpressed in neurogenic and nonneurogenic regions in sporadic Alzheimer's disease (AD) (32, 33) and adult Down syndrome (DS) brains (34, 35) . Moreover, pieces of experimental evidence associate Notch signaling with the progression of brain injury after stroke (36) and progno sis of certain brain tumors (37) . Regardless of the cause In the central nervous system, NICD mediates self-renewing divisions, and it has also been implicated in regulating quiescence of neural stem cells (NSCs). In progenitors, NICD is important for proliferation and de-differentiation. The most well-known role of Notch is the inhibition of neuronal differentiation of NSCs and progenitors. The activation of the canonical Notch signaling (CS) delays myelination, while the activation of the noncanonical pathway (NCS) leads to OPC maturation into oligodendrocytes (OL) and myelination of axons. By contrast, the role of NICD in the switch from neurogenesis to gliogenesis to generate astrocytes still presents controversies (dotted line).
of these diseases, AD, DS, and multiinfarct dementia present cognitive impairments and/or a neurodegenera tive phenotype, which highlight the importance of altered Notch signaling in the adult brain as a contributing factor to neuronal dysfunction. The roles of Notch signaling in CNS injury and disease are complex, involving multiple cell types (neurons, glial cells, vas cular cells, and lym phocytes), and either detrimental or bene ficial actions on the pathogenic process and functional outcome have been reported. In the follo wing section, we will discuss the role of Notch in nongenetic neurological diseases.
Brain ischemia
In ischemia or stroke, there is an increased neurogenesis mediated by the Notch signal in the SVZ and CA1 region of the hippocampus (38) , which is subsequently down regulated to promote neuronal differentiation. In addi tion, Notch signaling is also involved in the angiogenic process after ischemia as its activation is important in the reorganization of blood vessels branching during reper fusion (39) . Specifically, Notch regulates angiogenesis by controlling endothelial cell proliferation, migration, and adhesion (40) . It was demonstrated that after Notch inter action with δ and Jagged/Serrate (Table 1) , these ligands are cleaved similarly to the Notch receptor producing an intracellular domain, which inhibits endothelial cell proliferation but do not affect endothelial migration, sprouting angiogenesis or cell adhesion as shown for NICD (40) . The effect of NICD is regulated by its polyubiq uitination and proteasomal degradation. This process involves Fbxw7, an Fbox protein that acts as a substrate recognizing component of a type E3 ubiquitin ligase (41) . In Fbxw7 lossoffunction models, the lifetime of NICD is prolonged leading to a general slowdown in angiogene sis, sprouting, and proliferation of endothelial cells (42) . Vascular endothelial growth factors (VEGFs) have impor tant roles in the development and function of the circula tory and nervous systems, and their expression increases shortly after ischemia (43) . It has been suggested that decrements of Notch signaling allows an upregulation of VEGFR3 activity, which is proangiogenic in endothe lial cells and mimics aspects of cancer cells growth (44) . Brain ischemia is also characterized by an inflammatory response, and it is known that the Notch pathway modu lates the activation of inflammatory cells, such as lym phocytes and microglia. Increasing evidence indicates that Notch plays an important role in regulating the dif ferentiation of activated T cells into distinct types of effec tor T cells (45) . The trigger of Notch signaling induced by cerebral ischemia produces the activation of microglia by increasing NFκB activity (46) . In summary, Notch signal ing might be beneficial as a stimulator of proliferation of NSCs for repair, but might also impair the outcome by the inhibition of differentiation toward neurons and its parti cipation in the inflammatory response (36) . The roles of Notch during ischemia are complex, and the potential therapeutic benefits of inhibition or activation of the pathway require further studies.
Alzheimer's disease (AD) and Down syndrome (DS)
In postmitotic neurons of the adult brain, Notch mole cules are coexpressed and interact physically and func tionally with presenilins (PSs), the catalytic component of the γsecretase complex to generate NICD (as described above). The same γsecretase complex is also implicated in the proteolytic processing of the amyloid precursor protein (APP) to originate the amyloid β (Aβ) peptide (47) , which accumulates in the brain of AD (48) and DS patients (49) . Mutations in PSs genes are responsible for rare familial Alzheimer's disease (FAD) cases (50, 51) characterized by an increased proportion of the more amyloidogenic form of Aβ peptide (Aβ42) or increased levels of the less amyloido genic form of Aβ peptide (Aβ40) in the brain. A very recent report showed that expression of several FAD PS1 mutants in NSCs leads to impaired NSC selfrenewal due to a reduced γsecretase cleavage of Notch (52) suggesting that inhibition of Notch signaling may have a direct impact on the neurodegen erative phenotype observed in FAD brain. It was recently reported that neuro genesis and NSC renewal are both γsecretase activitydependent processes; however, the data showed that NSC renewal relays not only in Notch signaling but also on other substrates of γsecretases (33) . Post mortem studies on the status of neurogenesis in human AD patients have been contradictory with reports showing an increase in hippocampal neurogen esis (53) and others finding no differences (54) . Addi tionally, a potential decrease in progenitor cell numbers in AD (55) was associated with cortical cholinergic loss. Thus, AD may cause depletion of progenitor cells by pushing their cell fate to immature neurons or glial cells. It is plausible that decreased acti vity of NSCs in the SVZ of AD brains decreases the potential for spontane ous replacement of lost neurons in the cerebral cortex of AD brain. Neurogene sis has also been investigated in DS neurospheres isolated from post abortion fetal tissue. Considerably fewer neurons emerged after in vitro differentiation of neurospheres derived from the brain of DS compared to controls, while the numbers of glial cells remained unchanged. It is unclear though whether the number of neurons generated from these neurospheres was decreased due to increased apoptosis or due to a preferential differentiation of neurosphere cells into glia (56) . The lack of mutations and overexpression of APP in sporadic AD and in DS patients, respectively, sug gests that disturbances in Aβ clearance may be relevant to cerebral amyloid deposition in both diseases. In this context, it was recently demonstrated that Notch acti vation represses the transcription of insulin degrading enzyme (IDE), the major metalloprotease involved in the proteolysis of Aβ peptide in the brain (57) providing a novel functional link between Notch activation and Aβ accumulation in sporadic AD and DS cases (58) . These results are in agreement with pieces of experimental evidence showing that γsecretasemediated Notch sign aling worsens brain damage and functional outcome in ischemic stroke (59) , suggesting a potential role for Notch signaling in the pathogenesis of AD given that the inci dence of AD and vascular dementia is greatly increased following cerebral ischemia and stroke. The opposite activity of Notch in FAD compared to sporadic AD rein forces the striking differences between both clinical enti ties as suggested (60).
Multiple sclerosis
As previously described, Notch plays a critical role in the development of oligodendrocytes (OL) and has become a focus of attention in neurodegenerative dis eases where oligodendrocytes are lost and axons demye linated such as multiple sclerosis (MS). In the absence of pathology, Notch stimulates Schwann cell precursor differentiation and accelerates Schwann cell formation and proliferation in perinatal nerves during embryo genesis, but delays myelination in development and in adulthood (99) . In the developing rat optic nerve, the differentiation of oligodendrocyte precursor cells (OPCs) is inhibited by Notch activation. Notch1 is expressed in OPCs and Jagged1 in axons, and it has been proposed that the expression of Jagged1 is downregulated to allow myelination (89) . Thus, in this scenario, Notch seems to act as a restrictive rather than an instructive signal to keep the cells in their current developmental stage. On the contrary, the activation of the noncanonical Notch pathway by F3/contactin leads to OPC maturation and myelination via NICD/deltex interaction (61, 62, 100) . MS is a neuroinflammatory disease associated with demyelination that results in axonal degeneration. The process called remyelination can occur as a spontane ous regenerative process following demyelination. NSCs could be a potential source of OL, and it was demon strated that Notch signaling maintains the pool of NSCs in their undifferentiated state enabling the formation of OL (63, 64) . In demyelinating diseases, there is activa tion of astrocytes with increased JAG1 expression, and this signal blocks OPC differentiation and myelination (65) . Moreover, JAG1 is absent in remyelinated lesion, suggesting that JAG 1induced Notch signaling needs to be ended to allow myelin repair. Why the remyelinating processes fails in demyelinating diseases needs further study. However, Nakahara et al. (66) suggested that the problem in remyelination could be related to a failure of NICD nuclear transport after F3/contactin activation of Notch1 receptor in OPCs. In chronic demyelinated lesions, it was found that an increase in the expression of TATinteracting protein 30 kDa (TIP30), a direct inhibi tor of importin β, is the mediator of nuclear translocation of NICD (66) . These dual roles of Notch signaling through canonical and/or noncanonical pathways in the demy elinating and remyelinating process needs to be fully elucidated to assess its real therapeutic value.
Brain tumors
Gliomas (ependymomas, oligodendrogliomas, and astro cytomas) and medulloblastoma (brain tumor of the cere bellum) are the most common primary brain tumors in adults and children, respectively. These tumors are thought to arise from glial cells in which Notch signaling plays a fundamental role during development. Recent findings have shown that deregulated Notch signaling contributes to the malignant potential of these tumors (67) (68) (69) . Growing pieces of evidence point toward an important role for cancer stem cells in the initiation and maintenance of glioma and medulloblastoma. The study of human glioma specimens showed that Notch1 mRNA and protein expression were increased in the glioma cells compared with adjacent or normal tissue (67) . More over, this upregulation correlates with the severity of the disease (67) . Glioma cells share growth characteristics and gene expression patterns with normal NSCs. Several Notch ligands have been postulated to be responsible for the activation of Notch signaling within the glioma. A possible source of Notch ligands are endothelial cells adjacent to receptorpositive cancer cells (70, 71) . The extracellular matrix might also provide ligands for Notch, such as Fibulin3, a matrix protein that is absent in normal brain but upregulated in gliomas. Fibulin3 expression correlated with expression levels of Notch dependent genes (72) . Notch signaling is also involved in tumor angio genesis regulating VEGF actions (as described above). During development, VEGF stimu lates angiogenesis and lymphangiogenesis through the VEGFR2 and VEGFR3 tyrosine kinases expressed in endothelial cells. However, VEGFR3, whose expression is restricted to the lymphatic endothelium in adulthood, is upregulated in the microvasculature of tumor. It was suggested that VEGF induces the Notch ligand (DLL4) in endothelial cells and that Notch signaling activation by DLL4 reduces VEGF3 gene expression and endothelial sprouting (73, 74) . In addition to Notch signaling upreg ulation, increase in Sonic hedgehog (Shh) activity has been identified in medulloblastomas (75) . As Notch sign aling, Shh pathway has been implicated in a range of spo radic tumors in various organs and tissues (76) . Shh has a widespread expression pattern, and similarly to Notch, it plays an important role in differentiation and prolifera tion during development (77) . Shh signaling is primarily responsible for the dramatic expansion of the granule cell progenitor precursor pool in the cerebellum due to its mitogenic effect (78) . Likewise, Notch signaling also stim ulates granule cell proliferation through the upregulation of Hes1 (69) . Moreover, Hes1 expression is also induced by Shh in a noncanonical signaling, suggesting a common downstream effector of these two pathways (79) . Indeed, the inhibitions of Shh and Notch pathways showed a reduced tumor progression (80) .
A summary of the consequences of Notch signal ing activation in diseased adult brain is summarized in Table 2 .
Inhibition of Notch signaling as a therapeutic target in neurological diseases
The Notch pathway is dysregulated in different neuro logical diseases, and its pharmacological modulation may be a potential therapeutic target. Compounds cur rently described as modulators of Notch signaling include inhibitors of ADAM10 or γsecretase activity (which are necessary for Notch processing) and small molecules that act as posttranscriptional inhibitors of Notch. As ADAM10 is implicated in the shedding of dozens of substrates that drive cancer progression and inflammatory disease, including Ecadherin, EGF, ErbB2, and inflammatory cytokines, it has become the focus of intense interest as a potential drug target for disease treatment.
Different αsecretase inhibitors (ASI) and γsecretase inhibitors (GSIs) were tested for the inhibition of glioblas toma growth, and pieces of experimental evidence showed that: 1) the treatment of cultures obtained from glioma samples with GSIs reduced the proliferation of the cells and induced their differentiation (81), 2) In vitro studies on medulloblastoma growth demonstrated that treatment with GSIs did not deplete the totality of the cells, but a population required for tumor xenograft formation (82) . In contrast to these data, in vivo studies have pointed out that in Shh pathwaydriven medulloblastomas, Notch signaling is not essential for the initiation, engraftment, or maintenance of the tumor, and that inhibition of the Notch pathway might not be the most suitable therapeu tic approach (83); 3) Local nanoparticle delivery of ASIs, but not GSIs, increased the survival time significantly in a glioblastomas stem cell xenograft treatment model, decreased tumor size, and Notch activity (84) . This work indicates ASIs as an alternative to GSIs for treatment of glioblastomas and possibly other cancers as well. The potential of inhibition of Notch activity for the therapy of different brain tumors is currently under analysis in dif ferent preclinical assays (85) .
GSIs have also been tested in animal models of AD (86) in an attempt to treat patients by blocking the pro duction of Aβ peptides and subsequent plaque forma tion. Given that the potential patient population for the treatment of Alzheimer's disease is elderly, the profound effects of Notch disruption seen in embryonic and fetal development may not be of concern. However, it is now known that Notch signaling plays an important role in the ongoing differentiation processes of the immune system and the gastrointestinal tract. As a result, it may be nec essary to separate γsecretase activity on APP from Notch processing activity to achieve an adequate safety margin for clinical development of a GSI therapeutic agent for Alzheimer's disease. Additionally, GSIs were also tested for their potential utility in the treatment of ischemia. In this context, experiments in animal models showed that: 1) the administration of a GSI increased the number of newly generated hippocampal neurons in the CA1 region (87) reinforcing the concept that Notch signaling contrib utes to the regulation of neurogenesis in the adult brain after ischemia; 2) treatment of microglia with GSIs reduces NFκB/p65 nuclear translocation, together with a decrease in microglia proliferation and expression of IL1β and TNF α, critical inflammatory cytokines in the damage after the ischemic insult (88) .
While these studies highlight the significant progress in the development and potential efficacy of synthetic ASIs and GSIs, there are still many challenges to over come. For example, some in vitro studies have shown stimulusdependent redundancy for the ADAMs involved in specific shedding events, which if recapitulated in vivo, may limit the effectiveness of treatment with specific ADAM10 inhibitors (89) . Regarding GSIs, it is important to note that γsecretase is an unconventional aspartyl protease that resides and cleaves its substrates within the lipid bilayer. In fact, γsecretase complex belongs to a group of proteases called intramembrane cleaving pro teases (ICLiPs) that are membraneembedded enzymes. These enzymes hydrolyze transmembrane substrates, and the residues essential for catalysis reside within the boundaries of the lipid bilayer. γSecretase displays poor substrate specificity, but a functional γsecretase cleavage has been clearly demonstrated for some substrates such as Notch, Ncadherin, and ErB4. Proteolysis of Ncadherin leads to degradation of the transcriptional factor CREB binding protein (CBP), and cleavage of ErB4 inhibits astrocyte differentiation by interacting with repressors of astrocyte gene expression. The fact that GSIs block the processing of different proteins may be the main cause of toxicity in preclinical testing and represents a major source of concern in clinical trials. The discovery that some small organic molecules and some nonsteroi dal antiinflammatory drugs may modulate the cleavage activity of γsecretase on APP without interfering with the cleavage of other substrates has led to intensive efforts in designing γsecretase modulators that appear much more attractive from a safety point of view than traditional GSIs in the treatment of Alzheimer disease (90) . Emerging evidence implicates microRNAs (miRNAs) as being intimately involved in the regulation of Notch signaling and different neurological disorders such as tumors (acting as either oncogenes or tumor suppres sors), stroke, and hypoxia. MiRNAs are small noncoding RNA molecules that participate in all cellular processes of the organism, including development, differentiation, metabolism, and programmed cell death, among others (91, 92) . Pieces of experimental evidence showed that: 1) a particular miRNA, miR146a, acts as a tumor suppressor in gliomas through the inhibition of Notch1 posttranscrip tionally. miR146 seems to be able to integrate informa tion from various pathways to detect whether they are moving in a protumorigenesis direction and then coun teract that trend if necessary (93); 2) miR124a is preferen tially expressed in neurons and specifically binds to JAG1 mRNA suppressing its expression. Following a stroke, this miRNA is downregulated allowing JAG1 expression in the NSCs and promoting NSC proliferation by the Notch pathway activation (94); and 3) upregulation of miR210, a hypoxiaspecific miRNA, may activate the Notch pathway and promote vessel formation (95) . Knowledge acquired on miRNA function, expression, and deregulation has opened up new opportunities for therapeutic interven tion. Emerging preclinical studies are demonstrating the feasibility of inhibiting overexpressed miRNAs or restor ing the expression of lost miRNAs. The therapeutic use of miRNAs as single agents or in combination with current treatments may offer technical advantages over other approaches. However, in order to accelerate the transla tion of this knowledge into the clinics, several aspects must be improved and considered such as standardiza tion of pharmacological preparations, pharmacokinetic and pharmacodynamic analysis to ensure that therapeutic doses of miRNAs are achieved in target tissues, the inter action with the host immune system, as it may improve or weaken the therapeutic effects of a particular miRNA and the consequences of long treatment periods in human clinical settings.
Conclusions
The first description by J.S. Dexter of a Notch gene muta tion in Drosophila was made in March 1913 and now after nearly a century of research on Notch signaling, emerg ing concepts in the last years suggest that the develop mental functions of the Notch signaling pathway may be reused throughout life to guarantee brain adaptation. However, we still have much to learn about the many roles of Notch in neural functionality and the structure of axons and dendrites in adulthood. There has been an impressive recent progress in the comprehension that this simple signaling mechanism produces such a bewilder ing array of downstream consequences, including com pletely different effects in the same cell at different times. However, further in vivo experiments are necessary to better understand the relevance of the two Notch signal ing mechanisms (canonical and noncanonical), the dual roles of Notch signaling as a homeostatic factor both in health and disease. Conceptually, the identification of a link between two apparently distant physiopathological processes such as neurodevelopment and neurodegenera tion provides new perspectives in the pathophysiology of Notchrelated neurodegenerative diseases. However, due to the multiplicity of gene targets and cellular processes regulated by Notch, it is difficult to speculate about how its activation may impact upon the disease course. In summary, it is not inconceivable that future developments of genetic methods to manipulate Notch signaling in adult brain will provide pieces of novel evidence to encourage Notch modulation as an accepted target for medical treat ment of human diseases.
